Vaccell (TLP0-001) / Tella Pharma - LARVOL DELTA

Beroni Group Signs MoU with tella, Inc to Collaborate in Immunotherapy for Cancer Treatment (GlobeNewswire) - "Beroni Group...announced that it has signed a Memorandum of Understanding with tella, Inc. ('tella') to collaborate in the field of immunotherapy for cancer treatment...'This collaboration can help us provide dendritic cell vaccine therapy to more people in more geographical locations and more cancer patients can thus be cured.'"

Licensing / partnership • Oncology

A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy. (PubMed, Trials) - "Clinical trials of the standard regimen, including gemcitabine, for advanced pancreatic cancer are ongoing worldwide. However, a strategy for after the primary treatment has not been established. We therefore decided to conduct this study to evaluate the safety and efficacy of TLP0-001 as a secondary treatment for pancreatic cancer in anticipation of the approval of this new drug in Japan. This trial is conducted with full consideration of safety, as it is the first-in-human clinical trial of TLP0-001; thus, the trial will be conducted only at the Second Department of Surgery at Wakayama Medical University until the safety is confirmed by interim analysis. We plan to conduct a multicenter trial at 18 institutions in Japan after confirmation of the safety."

Clinical • Combination therapy • Journal